Page 92 - Genentech News Today

Targeted protein degraders such as proteolysis targeting chimeras (PROTACs) have been a significant development in the therapeutics space. These…

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct 11, 2023--

<p>EVEscape predicts future viral mutations, new variants using evolutionary, biological information<br />  </p>

The COVID-19 pandemic seemed like a never-ending parade of SARS-CoV-2 variants, each equipped with new ways to evade the immune system, leaving the world bracing for what would come next.

Treatment with single-agent venetoclax led to prolonged disease response in patients with chronic lymphocytic leukemia who had relapsed or become refractory to prior B-cell receptor inhibitors including ibrutinib and idelalisib, according to findings from a phase 2 study.

– Vabysmo showed robust and sustained retinal drying up to 72 weeks and a safety profile consistent with previous trials –– If approved by the FDA, RVO would be Vabysmo’s third indication in addition to wet age-related macular degeneration (AMD) and diabetic macular edema (DME) –– Vabysmo is the first and only treat...

Suspension from Quotation Description The securities of Kazia Therapeutics Limited will be suspended from quotation immediately under Listing Rule 17.2, at...

Faricimab maintained vision improvements and extended treatment intervals up to 4 months for people with RVO in the phase 3 BALATON and COMINO trials.

Nykode’s APC targeted vaccine technology can be delivered as mRNA and generate strong T cell responsesNykode’s APC targeted vaccine technology consistently results in faster, broader and stronger immune response compared to non-targeted vaccines, whether delivered as DNA or mRNA OSLO, Norway, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today ann...

Kristine Boyden, who was CCO at Cruise, the self-driving automobile company, will join BCW Oct. 16 as CEO Americas.